CN110143900B - 使用sirt2调节剂的治疗方法 - Google Patents

使用sirt2调节剂的治疗方法 Download PDF

Info

Publication number
CN110143900B
CN110143900B CN201910002021.XA CN201910002021A CN110143900B CN 110143900 B CN110143900 B CN 110143900B CN 201910002021 A CN201910002021 A CN 201910002021A CN 110143900 B CN110143900 B CN 110143900B
Authority
CN
China
Prior art keywords
sirt2
group
compound
sirt
carbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201910002021.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110143900A (zh
Inventor
林合宁
何彬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CN110143900A publication Critical patent/CN110143900A/zh
Application granted granted Critical
Publication of CN110143900B publication Critical patent/CN110143900B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201910002021.XA 2011-10-07 2012-10-05 使用sirt2调节剂的治疗方法 Expired - Fee Related CN110143900B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161544452P 2011-10-07 2011-10-07
US61/544,452 2011-10-07
CN201280059788.2A CN103974934B (zh) 2011-10-07 2012-10-05 使用sirt2调节剂的治疗方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280059788.2A Division CN103974934B (zh) 2011-10-07 2012-10-05 使用sirt2调节剂的治疗方法

Publications (2)

Publication Number Publication Date
CN110143900A CN110143900A (zh) 2019-08-20
CN110143900B true CN110143900B (zh) 2021-08-03

Family

ID=48044173

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910002021.XA Expired - Fee Related CN110143900B (zh) 2011-10-07 2012-10-05 使用sirt2调节剂的治疗方法
CN201280059788.2A Expired - Fee Related CN103974934B (zh) 2011-10-07 2012-10-05 使用sirt2调节剂的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280059788.2A Expired - Fee Related CN103974934B (zh) 2011-10-07 2012-10-05 使用sirt2调节剂的治疗方法

Country Status (6)

Country Link
US (2) US9359293B2 (enExample)
EP (1) EP2763962B1 (enExample)
CN (2) CN110143900B (enExample)
ES (1) ES2773266T3 (enExample)
IN (1) IN2014DN03077A (enExample)
WO (1) WO2013052727A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773266T3 (es) * 2011-10-07 2020-07-10 Univ Cornell Métodos de tratamiento utilizando moduladores de SIRT2
US9945865B2 (en) * 2013-03-22 2018-04-17 University Of Florida Research Foundation, Inc. Polymer nanocomposites for early diagnosis of diseases
US10556878B2 (en) * 2013-06-06 2020-02-11 Cornell University Thiourea compounds and their use as inhibitors of Sirt2 or Sirt5
CA3052622A1 (en) * 2017-02-03 2018-08-09 The Mclean Hospital Corporation Methods for manipulating cell fate
CN110551048B (zh) * 2018-06-04 2021-08-10 中国科学院上海药物研究所 一类sirt2抑制剂、其制备方法及用途
US12161639B2 (en) 2018-07-17 2024-12-10 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating PACS1 and PACS2 syndromes
CN114315670B (zh) * 2022-01-19 2024-03-29 贵州医科大学 一种sirt2/hdac6双靶标抑制剂及其应用
CN116178340B (zh) * 2023-04-28 2023-08-18 细胞生态海河实验室 一种protac化合物、制备方法及药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
CA2550958A1 (en) 2003-12-22 2005-07-07 Astellas Pharma Inc. Ornithine derivatives as prostaglandin e2 agonists or antagonists
US20070021434A1 (en) 2005-06-24 2007-01-25 Migenix Inc. Non-nucleoside anti-hepacivirus agents and uses thereof
WO2008080223A1 (en) 2006-12-28 2008-07-10 Migenix Inc. Compositions and methods for treating hyperproliferative disease
ES2773266T3 (es) * 2011-10-07 2020-07-10 Univ Cornell Métodos de tratamiento utilizando moduladores de SIRT2

Also Published As

Publication number Publication date
CN110143900A (zh) 2019-08-20
US9572789B2 (en) 2017-02-21
EP2763962B1 (en) 2019-12-04
CN103974934B (zh) 2019-07-23
WO2013052727A1 (en) 2013-04-11
US9359293B2 (en) 2016-06-07
US20160279091A1 (en) 2016-09-29
IN2014DN03077A (enExample) 2015-05-15
US20140249216A1 (en) 2014-09-04
EP2763962A4 (en) 2015-08-19
CN103974934A (zh) 2014-08-06
EP2763962A1 (en) 2014-08-13
ES2773266T3 (es) 2020-07-10

Similar Documents

Publication Publication Date Title
CN110143900B (zh) 使用sirt2调节剂的治疗方法
EP2596122B1 (en) Modulators for sirt5 and assays for screening same
US9872919B2 (en) Prodrugs for selective anticancer therapy
CZ144798A3 (cs) Nové makrocyklické sloučeniny jako metaloproteinázové inhibitory
US20160102336A1 (en) Fluorescent probe for detecting activity of calpain
US10072282B2 (en) Modulators for SIRT6 and assays for screening same
US20240391887A1 (en) New VASHs inhibitors, conjugates thereof and their uses as drugs or as research tools
EP3241823B1 (en) Pyrrole amide compound, preparation method therefor, and use thereof
US10556878B2 (en) Thiourea compounds and their use as inhibitors of Sirt2 or Sirt5
US20240228460A1 (en) Protease inhibitors and methods of making same
WO2008095296A1 (en) Class ii histone deacetylase whole cell enzyme assay
US12416036B2 (en) High-throughput enzyme assay for screening activity of acyltransferases
EP4433495A1 (en) Peptides and uses thereof
AU2021408143A1 (en) Cyclic peptides and uses thereof
MINGYU Chemical biology of metalloproteases and cysteine proteases
He et al. Thiolutin Derivatives as Psmd14/Hdac Dual-Target Inhibitors Against Esophageal Cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210803